Financial Review: NeurAxis (NASDAQ:NRXS) vs. Embecta (NASDAQ:EMBC)

Embecta (NASDAQ:EMBC) and NeurAxis (NASDAQ:NRXS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Analyst Ratings

This is a breakdown of current recommendations for Embecta and NeurAxis, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	2	3	0	0	1.60
NeurAxis	0	0	1	0	3.00

Embecta presently has a consensus target price of $11.00, indicating a potential upside of 114.84%. NeurAxis has a consensus target price of $13.00, indicating a potential upside of 126.88%. Given NeurAxis’ stronger consensus rating and higher probable upside, analysts plainly believe NeurAxis is more favorable than Embecta.

Volatility and Risk

Embecta has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Comparatively, NeurAxis has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500.

Insider & Institutional Ownership

93.8% of Embecta shares are owned by institutional investors. Comparatively, 11.8% of NeurAxis shares are owned by institutional investors. 1.3% of Embecta shares are owned by insiders. Comparatively, 21.1% of NeurAxis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Embecta and NeurAxis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Embecta	8.59%	-19.25%	10.82%
NeurAxis	-492.76%	N/A	-641.25%

Earnings & Valuation

This table compares Embecta and NeurAxis”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.08 billion	0.27	$95.40 million	$1.48	3.46
NeurAxis	$5.32 million	13.54	-$14.63 million	($0.78)	-7.35

Embecta has higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

About NeurAxis

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.